Attention-deficit/hyperactivity disorder (ADHD) is a disorder marked by an ongoing pattern of inattention and/or hyperactivity-impulsivity that interferes with functioning or development.

Inattention means a person wanders off task, lacks persistence, has difficulty sustaining focus, and is disorganized; and these problems are not due to defiance or lack of comprehension.

Hyperactivity means a person seems to move about constantly, including in situations in which it is not appropriate; or excessively fidgets, taps, or talks. In adults, it may be extreme restlessness or wearing others out with constant activity.

Impulsivity means a person makes hasty actions that occur in the moment without first thinking about them and that may have a high potential for harm, or a desire for immediate rewards or inability to delay gratification. An impulsive person may be socially intrusive and excessively interrupt others or make important decisions without considering the long-term consequences.

The global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.

North American market for Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.

Asia-Pacific market for Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.

The global market for Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics in Pediatric and Adolescents is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.

The major global companies of Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics include Pfizer, GSK, Eli Lilly, Novartis, Johnson & Johnson, Mallinckrodt, Hisamitsu, UCB and Takeda, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.

This report aims to provide a comprehensive presentation of the global market for Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics.

Report Scope

The Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

Scope of Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Report

Report Metric	Details
Report Name	Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market
Segment by Type	Stimulants Non-stimulants
Segment by Application	Pediatric and Adolescents Adults
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Pfizer, GSK, Eli Lilly, Novartis, Johnson & Johnson, Mallinckrodt, Hisamitsu, UCB, Takeda, Purdue Pharma, Impax Laboratories
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

FAQ for this report

Who are the main players in the Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market report?

Ans: The main players in the Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market are Pfizer, GSK, Eli Lilly, Novartis, Johnson & Johnson, Mallinckrodt, Hisamitsu, UCB, Takeda, Purdue Pharma, Impax Laboratories

What are the Application segmentation covered in the Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market report?

Ans: The Applications covered in the Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market report are Pediatric and Adolescents, Adults

What are the Type segmentation covered in the Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market report?

Ans: The Types covered in the Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market report are Stimulants, Non-stimulants

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size Growth Rate by Type: 2019 VS 2023 VS 2030

1.2.2 Stimulants

1.2.3 Non-stimulants

1.3 Market by Application

1.3.1 Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Growth by Application: 2019 VS 2023 VS 2030

1.3.2 Pediatric and Adolescents

1.3.3 Adults

1.4 Study Objectives

1.5 Years Considered

1.6 Years Considered

2 Global Growth Trends

2.1 Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Perspective (2019-2030)

2.2 Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Growth Trends by Region

2.2.1 Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Region: 2019 VS 2023 VS 2030

2.2.2 Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Historic Market Size by Region (2019-2024)

2.2.3 Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Forecasted Market Size by Region (2025-2030)

2.3 Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Dynamics

2.3.1 Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Industry Trends

2.3.2 Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Drivers

2.3.3 Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Challenges

2.3.4 Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Players by Revenue

3.1.1 Global Top Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Players by Revenue (2019-2024)

3.1.2 Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue Market Share by Players (2019-2024)

3.2 Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Players Covered: Ranking by Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue

3.4 Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Concentration Ratio

3.4.1 Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue in 2023

3.5 Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Key Players Head office and Area Served

3.6 Key Players Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Product Solution and Service

3.7 Date of Enter into Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market

3.8 Mergers & Acquisitions, Expansion Plans

4 Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Breakdown Data by Type

4.1 Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Historic Market Size by Type (2019-2024)

4.2 Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Forecasted Market Size by Type (2025-2030)

5 Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Breakdown Data by Application

5.1 Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Historic Market Size by Application (2019-2024)

5.2 Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Forecasted Market Size by Application (2025-2030)

6 North America

6.1 North America Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size (2019-2030)

6.2 North America Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030

6.3 North America Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Country (2019-2024)

6.4 North America Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Country (2025-2030)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size (2019-2030)

7.2 Europe Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030

7.3 Europe Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Country (2019-2024)

7.4 Europe Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Country (2025-2030)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Nordic Countries

8 Asia-Pacific

8.1 Asia-Pacific Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size (2019-2030)

8.2 Asia-Pacific Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Growth Rate by Region: 2019 VS 2023 VS 2030

8.3 Asia-Pacific Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Region (2019-2024)

8.4 Asia-Pacific Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Region (2025-2030)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia

9 Latin America

9.1 Latin America Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size (2019-2030)

9.2 Latin America Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030

9.3 Latin America Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Country (2019-2024)

9.4 Latin America Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Country (2025-2030)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size (2019-2030)

10.2 Middle East & Africa Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030

10.3 Middle East & Africa Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Country (2019-2024)

10.4 Middle East & Africa Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Country (2025-2030)

10.5 Turkey

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 Pfizer

11.1.1 Pfizer Company Detail

11.1.2 Pfizer Business Overview

11.1.3 Pfizer Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Introduction

11.1.4 Pfizer Revenue in Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Business (2019-2024)

11.1.5 Pfizer Recent Development

11.2 GSK

11.2.1 GSK Company Detail

11.2.2 GSK Business Overview

11.2.3 GSK Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Introduction

11.2.4 GSK Revenue in Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Business (2019-2024)

11.2.5 GSK Recent Development

11.3 Eli Lilly

11.3.1 Eli Lilly Company Detail

11.3.2 Eli Lilly Business Overview

11.3.3 Eli Lilly Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Introduction

11.3.4 Eli Lilly Revenue in Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Business (2019-2024)

11.3.5 Eli Lilly Recent Development

11.4 Novartis

11.4.1 Novartis Company Detail

11.4.2 Novartis Business Overview

11.4.3 Novartis Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Introduction

11.4.4 Novartis Revenue in Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Business (2019-2024)

11.4.5 Novartis Recent Development

11.5 Johnson & Johnson

11.5.1 Johnson & Johnson Company Detail

11.5.2 Johnson & Johnson Business Overview

11.5.3 Johnson & Johnson Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Introduction

11.5.4 Johnson & Johnson Revenue in Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Business (2019-2024)

11.5.5 Johnson & Johnson Recent Development

11.6 Mallinckrodt

11.6.1 Mallinckrodt Company Detail

11.6.2 Mallinckrodt Business Overview

11.6.3 Mallinckrodt Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Introduction

11.6.4 Mallinckrodt Revenue in Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Business (2019-2024)

11.6.5 Mallinckrodt Recent Development

11.7 Hisamitsu

11.7.1 Hisamitsu Company Detail

11.7.2 Hisamitsu Business Overview

11.7.3 Hisamitsu Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Introduction

11.7.4 Hisamitsu Revenue in Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Business (2019-2024)

11.7.5 Hisamitsu Recent Development

11.8 UCB

11.8.1 UCB Company Detail

11.8.2 UCB Business Overview

11.8.3 UCB Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Introduction

11.8.4 UCB Revenue in Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Business (2019-2024)

11.8.5 UCB Recent Development

11.9 Takeda

11.9.1 Takeda Company Detail

11.9.2 Takeda Business Overview

11.9.3 Takeda Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Introduction

11.9.4 Takeda Revenue in Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Business (2019-2024)

11.9.5 Takeda Recent Development

11.10 Purdue Pharma

11.10.1 Purdue Pharma Company Detail

11.10.2 Purdue Pharma Business Overview

11.10.3 Purdue Pharma Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Introduction

11.10.4 Purdue Pharma Revenue in Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Business (2019-2024)

11.10.5 Purdue Pharma Recent Development

11.11 Impax Laboratories

11.11.1 Impax Laboratories Company Detail

11.11.2 Impax Laboratories Business Overview

11.11.3 Impax Laboratories Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Introduction

11.11.4 Impax Laboratories Revenue in Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Business (2019-2024)

11.11.5 Impax Laboratories Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.2 Data Source

13.2 Disclaimer

13.3 Author Details

FEATURED COMPANIES

List of Tables

Table 1. Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030

Table 2. Key Players of Stimulants

Table 3. Key Players of Non-stimulants

Table 4. Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030

Table 5. Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Region (US$ Million): 2019 VS 2023 VS 2030

Table 6. Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Region (2019-2024) & (US$ Million)

Table 7. Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Share by Region (2019-2024)

Table 8. Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Forecasted Market Size by Region (2025-2030) & (US$ Million)

Table 9. Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Share by Region (2025-2030)

Table 10. Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Trends

Table 11. Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Drivers

Table 12. Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Challenges

Table 13. Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Restraints

Table 14. Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue by Players (2019-2024) & (US$ Million)

Table 15. Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Share by Players (2019-2024)

Table 16. Global Top Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics as of 2023)

Table 17. Ranking of Global Top Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Companies by Revenue (US$ Million) in 2023

Table 18. Global 5 Largest Players Market Share by Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue (CR5 and HHI) & (2019-2024)

Table 19. Key Players Headquarters and Area Served

Table 20. Key Players Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Product Solution and Service

Table 21. Date of Enter into Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market

Table 22. Mergers & Acquisitions, Expansion Plans

Table 23. Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Type (2019-2024) & (US$ Million)

Table 24. Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue Market Share by Type (2019-2024)

Table 25. Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Forecasted Market Size by Type (2025-2030) & (US$ Million)

Table 26. Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue Market Share by Type (2025-2030)

Table 27. Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Application (2019-2024) & (US$ Million)

Table 28. Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue Market Share by Application (2019-2024)

Table 29. Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Forecasted Market Size by Application (2025-2030) & (US$ Million)

Table 30. Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue Market Share by Application (2025-2030)

Table 31. North America Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 32. North America Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Country (2019-2024) & (US$ Million)

Table 33. North America Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Country (2025-2030) & (US$ Million)

Table 34. Europe Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 35. Europe Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Country (2019-2024) & (US$ Million)

Table 36. Europe Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Country (2025-2030) & (US$ Million)

Table 37. Asia-Pacific Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030

Table 38. Asia-Pacific Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Region (2019-2024) & (US$ Million)

Table 39. Asia-Pacific Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Region (2025-2030) & (US$ Million)

Table 40. Latin America Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 41. Latin America Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Country (2019-2024) & (US$ Million)

Table 42. Latin America Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Country (2025-2030) & (US$ Million)

Table 43. Middle East & Africa Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 44. Middle East & Africa Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Country (2019-2024) & (US$ Million)

Table 45. Middle East & Africa Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Country (2025-2030) & (US$ Million)

Table 46. Pfizer Company Detail

Table 47. Pfizer Business Overview

Table 48. Pfizer Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Product

Table 49. Pfizer Revenue in Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Business (2019-2024) & (US$ Million)

Table 50. Pfizer Recent Development

Table 51. GSK Company Detail

Table 52. GSK Business Overview

Table 53. GSK Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Product

Table 54. GSK Revenue in Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Business (2019-2024) & (US$ Million)

Table 55. GSK Recent Development

Table 56. Eli Lilly Company Detail

Table 57. Eli Lilly Business Overview

Table 58. Eli Lilly Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Product

Table 59. Eli Lilly Revenue in Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Business (2019-2024) & (US$ Million)

Table 60. Eli Lilly Recent Development

Table 61. Novartis Company Detail

Table 62. Novartis Business Overview

Table 63. Novartis Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Product

Table 64. Novartis Revenue in Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Business (2019-2024) & (US$ Million)

Table 65. Novartis Recent Development

Table 66. Johnson & Johnson Company Detail

Table 67. Johnson & Johnson Business Overview

Table 68. Johnson & Johnson Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Product

Table 69. Johnson & Johnson Revenue in Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Business (2019-2024) & (US$ Million)

Table 70. Johnson & Johnson Recent Development

Table 71. Mallinckrodt Company Detail

Table 72. Mallinckrodt Business Overview

Table 73. Mallinckrodt Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Product

Table 74. Mallinckrodt Revenue in Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Business (2019-2024) & (US$ Million)

Table 75. Mallinckrodt Recent Development

Table 76. Hisamitsu Company Detail

Table 77. Hisamitsu Business Overview

Table 78. Hisamitsu Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Product

Table 79. Hisamitsu Revenue in Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Business (2019-2024) & (US$ Million)

Table 80. Hisamitsu Recent Development

Table 81. UCB Company Detail

Table 82. UCB Business Overview

Table 83. UCB Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Product

Table 84. UCB Revenue in Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Business (2019-2024) & (US$ Million)

Table 85. UCB Recent Development

Table 86. Takeda Company Detail

Table 87. Takeda Business Overview

Table 88. Takeda Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Product

Table 89. Takeda Revenue in Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Business (2019-2024) & (US$ Million)

Table 90. Takeda Recent Development

Table 91. Purdue Pharma Company Detail

Table 92. Purdue Pharma Business Overview

Table 93. Purdue Pharma Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Product

Table 94. Purdue Pharma Revenue in Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Business (2019-2024) & (US$ Million)

Table 95. Purdue Pharma Recent Development

Table 96. Impax Laboratories Company Detail

Table 97. Impax Laboratories Business Overview

Table 98. Impax Laboratories Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Product

Table 99. Impax Laboratories Revenue in Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Business (2019-2024) & (US$ Million)

Table 100. Impax Laboratories Recent Development

Table 101. Research Programs/Design for This Report

Table 102. Key Data Information from Secondary Sources

Table 103. Key Data Information from Primary Sources

List of Figures

Figure 1. Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size Comparison by Type (2024-2030) & (US$ Million)

Figure 2. Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Share by Type: 2023 VS 2030

Figure 3. Stimulants Features

Figure 4. Non-stimulants Features

Figure 5. Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size Comparison by Application (2024-2030) & (US$ Million)

Figure 6. Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Share by Application: 2023 VS 2030

Figure 7. Pediatric and Adolescents Case Studies

Figure 8. Adults Case Studies

Figure 9. Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Report Years Considered

Figure 10. Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size (US$ Million), Year-over-Year: 2019-2030

Figure 11. Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size, (US$ Million), 2019 VS 2023 VS 2030

Figure 12. Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Share by Region: 2023 VS 2030

Figure 13. Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Share by Players in 2023

Figure 14. Global Top Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics as of 2023)

Figure 15. The Top 10 and 5 Players Market Share by Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue in 2023

Figure 16. North America Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 17. North America Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Share by Country (2019-2030)

Figure 18. United States Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 19. Canada Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 20. Europe Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 21. Europe Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Share by Country (2019-2030)

Figure 22. Germany Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 23. France Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 24. U.K. Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 25. Italy Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 26. Russia Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 27. Nordic Countries Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 28. Asia-Pacific Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 29. Asia-Pacific Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Share by Region (2019-2030)

Figure 30. China Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 31. Japan Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 32. South Korea Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 33. Southeast Asia Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 34. India Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 35. Australia Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 36. Latin America Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 37. Latin America Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Share by Country (2019-2030)

Figure 38. Mexico Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 39. Brazil Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 40. Middle East & Africa Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 41. Middle East & Africa Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Share by Country (2019-2030)

Figure 42. Turkey Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 43. Saudi Arabia Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 44. Pfizer Revenue Growth Rate in Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Business (2019-2024)

Figure 45. GSK Revenue Growth Rate in Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Business (2019-2024)

Figure 46. Eli Lilly Revenue Growth Rate in Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Business (2019-2024)

Figure 47. Novartis Revenue Growth Rate in Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Business (2019-2024)

Figure 48. Johnson & Johnson Revenue Growth Rate in Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Business (2019-2024)

Figure 49. Mallinckrodt Revenue Growth Rate in Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Business (2019-2024)

Figure 50. Hisamitsu Revenue Growth Rate in Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Business (2019-2024)

Figure 51. UCB Revenue Growth Rate in Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Business (2019-2024)

Figure 52. Takeda Revenue Growth Rate in Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Business (2019-2024)

Figure 53. Purdue Pharma Revenue Growth Rate in Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Business (2019-2024)

Figure 54. Impax Laboratories Revenue Growth Rate in Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Business (2019-2024)

Figure 55. Bottom-up and Top-down Approaches for This Report

Figure 56. Data Triangulation

Figure 57. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

120 Pages

Type: Report

Code: QYRE-Auto-35C377

Wed Mar 19 00:00:00 UTC 2025

$8000

Enterprise User

Add to Cart

Global Syndrome Progressive Ataxia Weakness Disorder Treatment Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-29C12714

Wed Mar 12 00:00:00 UTC 2025

$5800

Enterprise User

Add to Cart

Global Intracranial Treatment Drug Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-5M14436

Wed Mar 12 00:00:00 UTC 2025

$5800

Enterprise User

Add to Cart

Global Epilepsy Detection Alert Device Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-26Q12678

Wed Mar 12 00:00:00 UTC 2025

$5800

Enterprise User

Add to Cart

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions

Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Research Report 2024

Published Date: April 2024

Report Code: QYRE-Auto-39T5731

Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Research Report 2024

FEATURED COMPANIES

Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market

Report Scope

Scope of Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Report

Chapter Outline

FAQ for this report

Who are the main players in the Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market report?

What are the Application segmentation covered in the Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market report?

What are the Type segmentation covered in the Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market report?

FEATURED COMPANIES

RELATED REPORTS

$8000

Enterprise User

$5800

Enterprise User

$5800

Enterprise User

$5800

Enterprise User